NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization71.11 mln
Float26.53 mln
Earnings Date11/18/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
11.70
Transformational upside
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-61.79
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Tenax Therapeutics is a US-based pharmaceutical company focused on developing new treatments for heart and lung conditions. Its lead programs include levosimendan, which has completed Phase II trials for pulmonary hypertension in heart failure patients, and imatinib, a targeted therapy originally used in certain blood cancers. Founded in 1967 and based in Chapel Hill, North Carolina, the company rebranded from Oxygen Biotherapeutics in 2014.
